Lymphomas Flashcards
What are risk factors for HL?
EBV, HIV
Immunosuppression
What is the presentation of HL?
Asymptomatic lymphadenopathy
Discovery of mediastinal mass on x-ray
B-symptoms
Pain following alcohol consumption
What is asymptomatic lymphadenopathy?
Persisting for > 1 month, may wax and wane
Painless, rubbery
Nodal involvement usually systematic or logical
What are B-symptoms?
> 10% wt loss in 6 months
Fever
Night sweats
Pruritus
What types of cells are associated with HL?
Reed-sternberg cells
What type of imaging technique is used to diagnose HL?
Integrated PET/CT scan
What is Stage I from Cotswolds-Ann Arbor system?
Single lymph node region or lymphoid structure
What is stage II from Cotswolds-Ann Arbor system?
Multiple lymph nodes on same side of diaphragm
What is stage III from Cotswolds-Ann Arbor system?
Multiple lymph nodes on both sides of diaphragm
What is stage IV from Cotswolds-Ann Arbor system?
Lymph node involvement and extensive involvement of liver, lung, bone marrow, or another extralymphatic organ
What does A stand for in the Cotswolds-Ann Arbor system?
Absence of systemic symptoms
What does B stand for in the Cotswolds-Ann Arbor system?
B symptoms
What does the E stand for in the Cotswolds-Ann Arbor system?
Extranodal involvement
What are unfavorable factors in HL?
Bulky disease (mass > 10 cm)
ESR > 50 (if asx)
> 3 sites
B symptoms
What are the factors used in the IPI for HL?
Serum albumin (< 4) Hgb (< 10.5) Male Stage IV Age (45+) WBC (> 15,000) Lymphopenia (< 600 or <8% of WBC count)
What is the goal for HL?
Maximize potential for cure
What is the standard of care for HL?
ABVD
What is ABVD?
Doxorubicin
Bleomycin
Vinblastine
Dacarbazine
What are the stage I/II (favorable) treatment options?
Chemo +/- involved site radiation therapy (ISRT)
After 2-4 cycles, restage PET/CT
What are thestage I/II (unfavorable) and advanced disease treatment options?
Chemo (ABVD)
After chemo - restage, then chemo/ISRT
What are options for relapsed HL diseases?
Autologous HSCT HD chemo Everolimus Lenalidomide Nivolumab/pembrolizumab